These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 34425136)

  • 1. Modelling COVID-19 dynamics and potential for herd immunity by vaccination in Austria, Luxembourg and Sweden.
    Kemp F; Proverbio D; Aalto A; Mombaerts L; Fouquier d'Hérouël A; Husch A; Ley C; Gonçalves J; Skupin A; Magni S
    J Theor Biol; 2021 Dec; 530():110874. PubMed ID: 34425136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model based estimation of the SARS-CoV-2 immunization level in austria and consequences for herd immunity effects.
    Bicher M; Rippinger C; Schneckenreither G; Weibrecht N; Urach C; Zechmeister M; Brunmeir D; Huf W; Popper N
    Sci Rep; 2022 Feb; 12(1):2872. PubMed ID: 35190590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the impact of interventions against COVID-19: From lockdown to vaccination.
    Thompson J; Wattam S
    PLoS One; 2021; 16(12):e0261330. PubMed ID: 34919576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward Achieving a Vaccine-Derived Herd Immunity Threshold for COVID-19 in the U.S.
    Gumel AB; Iboi EA; Ngonghala CN; Ngwa GA
    Front Public Health; 2021; 9():709369. PubMed ID: 34368071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Modeling Outcome versus Reality in Sweden.
    Carlsson M; Söderberg-Nauclér C
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herd immunity: challenges and the way forward in Korea.
    Oh J; Kim S; Ryu B; Shin M; Kim BI
    Epidemiol Health; 2021; 43():e2021054. PubMed ID: 34412446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can Africa achieve herd immunity?
    Lucero-Prisno DE; Ogunkola IO; Esu EB; Adebisi YA; Lin X; Li H
    Glob Health Res Policy; 2021 Dec; 6(1):46. PubMed ID: 34852844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network models to evaluate vaccine strategies towards herd immunity in COVID-19.
    Tetteh JNA; Nguyen VK; Hernandez-Vargas EA
    J Theor Biol; 2021 Dec; 531():110894. PubMed ID: 34508758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Great Expectations of COVID-19 Herd Immunity.
    Giurgea LT; Morens DM
    mBio; 2022 Feb; 13(1):e0349521. PubMed ID: 35073740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Vaccination Rates on the Infection of COVID-19 under the Vaccination Rate below the Herd Immunity Threshold.
    Chen YT
    Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34299942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Social restriction versus herd immunity policies in the early phase of the SARS-CoV-2 pandemic: A mathematical modelling study.
    Chancharoenthana W; Leelahavanichkul A; Chinpraditsuk S; Pongpirul K; Kamolratanakul S; Phumratanaprapin W; Wilairatana P; Pitisuttithum P
    Asian Pac J Allergy Immunol; 2023 Sep; 41(3):253-262. PubMed ID: 33386788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Microbiota: A Paradigm for Evolving Herd Immunity against Viral Diseases.
    Shelly A; Gupta P; Ahuja R; Srichandan S; Meena J; Majumdar T
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33050511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brazil's COVID-19 Epicenter in Manaus: How Much of the Population Has Already Been Exposed and Are Vulnerable to SARS-CoV-2?
    Ferrante L; Duczmal LH; Steinmetz WA; Almeida ACL; Leão J; Vassão RC; Tupinambás U; Fearnside PM
    J Racial Ethn Health Disparities; 2022 Dec; 9(6):2098-2104. PubMed ID: 34590244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of serological surveys of antibodies to SARS-CoV-2 in the United States to estimate parameters needed for transmission modeling and to evaluate and improve the accuracy of predictions.
    Glasser JW; Feng Z; Vo M; Jones JN; Clarke KEN
    J Theor Biol; 2023 Jan; 556():111296. PubMed ID: 36208669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
    McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
    Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies.
    Beukenhorst AL; Koch CM; Hadjichrysanthou C; Alter G; de Wolf F; Anderson RM; Goudsmit J
    Eur J Epidemiol; 2023 Mar; 38(3):237-242. PubMed ID: 36738380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in Engendering Herd Immunity to SARS-CoV-2 Infection: Possibly Impossible But Plausibile.
    Mukherjee S; Ray SK
    Infect Disord Drug Targets; 2022; 22(4):e170122200309. PubMed ID: 35040409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges of vaccination and herd immunity in COVID-19 and management strategies.
    She J; Hou D; Chen C; Bi J; Song Y
    Clin Respir J; 2022 Nov; 16(11):708-716. PubMed ID: 36172975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.